Shareholder meetings, this week and ahead.

Election of 11 directors; Ratification of Ernst & Young LLP as independent auditors; Advisory vote to approve named executive officer compensation (Say-on-Pay); Approval of an amendment to provide officer exculpation in the charter; Advisory vote on shareholder proposal to lower the special-meeting threshold to 10% (if properly presented).

Four proposals: (1) Elect Class I director nominees Johanna Flower and Denis J. O’Leary; (2) Ratify PricewaterhouseCoopers LLP as independent auditor for fiscal year ending January 31, 2027; (3) Approve an amendment and restatement of the certificate of incorporation to limit officer liability as permitted by Delaware law; and (4) Advisory (non-binding) ratification of supermajority voting provisions in the certificate of incorporation and bylaws — the Board recommends "FOR" all proposals.

Election of 11 directors; Ratification of PwC as independent auditors; Advisory (non-binding) approval of named executive officer compensation (“say-on-pay”); Stockholder proposal to lower the special meeting ownership threshold to 10% (proponent John Chevedden).

Elect 11 directors; advisory (non-binding) approval of 2025 named executive officer compensation (say-on-pay); and ratification of Ernst & Young LLP as independent registered public accounting firm for 2026.

Elect two Class II directors (Ian Clark and Manuel Hidalgo Medina); ratify Deloitte & Touche LLP as independent auditors; approve, on a non-binding advisory basis, the compensation of the named executive officers (say-on-pay); and indicate the frequency of future say-on-pay votes (board recommends ONE YEAR).

Elect three Class I directors; approve, on a non-binding advisory basis, executive compensation; ratify PricewaterhouseCoopers LLP as independent auditor; approve the Madrigal Pharmaceuticals, Inc. 2026 Stock Plan; approve the Madrigal Pharmaceuticals, Inc. 2026 Employee Stock Purchase Plan; and transact any other properly presented business.

Elect ten directors to one-year terms; a non-binding advisory vote to approve the compensation of the Company’s named executive officers (say-on-pay); and ratify Deloitte & Touche LLP as the Company’s independent registered public accounting firm for 2026.

Election of nine directors; Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending January 31, 2027.

Elect eleven directors; advisory approval of 2025 named executive officer compensation (Say-on-Pay); ratify Ernst & Young LLP as independent auditor for fiscal 2026.

Shareholders will vote to elect ten directors; approve on an advisory basis the compensation of named executive officers (say-on-pay) and the frequency of future say-on-pay votes; ratify PricewaterhouseCoopers LLP as the independent auditor; and consider three shareholder proposals on majority-vote governance, a report on GHG emissions reduction efforts, and a report on deforestation risks in the company’s private‑label supply chain.

Election of 14 directors; advisory vote on executive compensation; ratification of Ernst & Young LLP as auditors; shareholder proposal to permit shareholder action by written consent (opposed by board); shareholder proposal to adopt cumulative voting for director elections (opposed by board).

Elect ten trustees to serve until 2027; ratify Ernst & Young LLP as the Company’s independent registered public accounting firm for 2026; and approve, on a non-binding advisory basis, the executive compensation disclosed in the proxy statement (Say-on-Pay).

Proposals include election of directors (Diana’s nominees Jens Ismar and Paul Cornell and Genco nominees Basil G. Mavroleon and Arthur L. Regan), ratification/extension of Genco’s shareholder rights plan (poison pill), approval of Genco’s equity incentive plan, Diana’s shareholder proposal to repeal Genco by‑laws not publicly disclosed on or prior to August 28, 2025, and Diana’s shareholder proposal requesting the Genco board conduct a process to explore strategic alternatives.

Elect two Class III directors; ratify Ernst & Young LLP as independent auditors; approve, on an advisory non-binding basis, the compensation of the company’s named executive officers (Say-on-Pay); and approve an amendment to the 2017 Equity Incentive Plan.

Three proposals: (1) election of three Class II directors; (2) ratification of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for fiscal 2026; and (3) a non-binding advisory (Say-on-Pay) vote to approve the compensation of the Company’s named executive officers for fiscal 2025.

Elect two Class III directors; ratify PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal 2026; and approve, on a non-binding advisory basis, the 2025 compensation of the company’s named executive officers (Say-on-Pay).

Re-appoint seven directors; ratify Ernst & Young LLP as independent auditors; approve, on a non-binding advisory basis, the compensation of named executive officers; select the frequency of future advisory votes on executive compensation (management recommends one year); and approve an amendment and restatement of the Memorandum and Articles of Association.

Election of eight directors; an advisory 'Say on Pay' vote to approve executive compensation; and ratification of Deloitte & Touche LLP as the Company’s independent registered public accounting firm.

Vote to fix the Board size at eleven and elect eleven director nominees; and a non-binding advisory "Say on Pay" vote to approve the compensation of the Corporation’s named executive officers as disclosed in the proxy statement.

Five proposals: (1) Elect three Class I directors (James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantine, M.D.); (2) Non-binding, advisory vote to approve named executive officer compensation (say-on-pay); (3) Non-binding, advisory vote on the frequency of future say-on-pay votes (one, two, or three years); (4) Ratify Deloitte & Touche LLP as the independent registered public accounting firm for 2026; (5) Approve an amendment and restatement of the 2021 Stock Option and Incentive Plan to increase the number of shares reserved for issuance by 2,000,000 shares.

Elect two Class III directors (Brett Schulman and James D. White) for three-year terms; approve, on an advisory basis, the compensation of the Company’s named executive officers (say-on-pay); and ratify Deloitte & Touche LLP as the Company’s independent registered public accounting firm for fiscal 2026.

Elect two Class II directors (Karen Boone and Aidan Gomez), ratify KPMG LLP as the independent registered public accounting firm for 2026, and approve on an advisory (non-binding) basis the 2025 compensation of the named executive officers (say-on-pay).

Election of eight directors; Ratification of Ernst & Young LLP as independent auditor; Advisory approval of executive compensation (say-on-pay); Approval of the CoStar Group, Inc. 2026 Employee Stock Purchase Plan; and transacting any other business properly presented.

Election of ten directors; advisory (non-binding) approval of executive compensation; ratification of PwC as independent auditor; and four stockholder proposals on adopting a simple majority vote standard, reporting on faith-based community resource groups, reporting on workforce civil liberties related to DEI, and disclosing greenhouse gas emissions from use of sold products.

Election of 12 directors; Ratification of KPMG LLP as independent registered public accounting firm for 2026; Advisory approval of named executive officers’ compensation (Say-on-Pay).

Election of seven Group I directors and one Group IV director; Ratification of PwC as independent auditors; Advisory Say-on-Pay approval of named executive officer compensation; Approval to redomesticate Dell Technologies Inc. from Delaware to Texas by conversion.

Election of 10 directors; Advisory approval of named executive officer compensation; Ratification of independent auditors (PricewaterhouseCoopers LLP); Approval of the 2019 Second Amended and Restated Long-Term Incentive Plan (increase share reserve and extend term); Shareholder proposal requesting a report on GHG emissions reductions (recommended against by the Board).

Election of three Class I directors (three company nominees), ratification of PricewaterhouseCoopers LLP as independent auditor, an advisory say-on-pay vote on executive compensation, approval to increase the share reserve under the 2023 Equity Incentive Plan, and a stockholder proposal to declassify the board so all directors are elected annually.

Elect eight directors; advisory (non-binding) approval of named executive officer compensation (Say-on-Pay); ratify Deloitte & Touche LLP as independent auditor; and vote on a stockholder proposal to require an independent Board chairman.

Election of 13 directors; advisory approval of executive compensation (say-on-pay); ratification of Ernst & Young LLP as independent registered public accounting firm; re-appointment of Ernst & Young Ireland as statutory auditor and authorization for its remuneration; renewal of authority for the Board to issue Class A Ordinary Shares under Irish law; and renewal of authority for the Board to opt-out of statutory pre-emption rights under Irish law.

Four proposals: (1) election of twelve directors; (2) an advisory “say-on-pay” vote to approve executive compensation; (3) approval of the United Therapeutics Corporation 2026 Stock Incentive Plan; and (4) ratification of Ernst & Young LLP as the company’s independent registered public accounting firm for 2026.

Elect three Class III directors; approve, on a non-binding advisory basis, executive compensation (Say-on-Pay); ratify PwC as independent auditors; and consider a stockholder proposal to adopt majority vote for director elections.

Election of three Class I directors; ratification of KPMG as auditors; advisory approval of executive compensation; approval and adoption of amended and restated certificate of incorporation (Proposals 4A–4F) including Class C non-voting stock, Series FF preferred stock and related governance changes; amendment and restatement of 2019 Equity Incentive Plan; amendment and restatement of Employee Stock Purchase Plan (ESPP); and approval of one or more adjournments if needed.

Elect 11 directors; ratify KPMG as independent auditor for 2026; approve, on an advisory basis, executive compensation (say-on-pay); and transact other business that may properly come before the meeting.

Election of three Class III directors; advisory approval of named executive officer compensation (‘say-on-pay’); ratification of PricewaterhouseCoopers LLP as independent auditors; approval of an amendment to the Certificate of Incorporation to eliminate supermajority vote requirements.